Vivek Ramaswamy’s brother, Shankar, spins out on his own, launching audacious gene therapy play
In 2018, when Vivek Ramaswamy’s Axovant failed multiple trials on its lead dementia drug and pivoted the entire company toward gene therapy, one employee took a particular liking to the new science: Vivek’s brother, Shankar Ramaswamy.
Now Shankar, who was hired as one of Roivant’s first 10 employees while still in medical school, is striking out on his own. Alongside a former Spark Therapeutics co-founder and a supporting cast drawn from some of the biggest name gene therapy biotechs, he’s raised $80 million around a vision of building a massive gene therapy company that can tackle diseases more prevalent than the rare genetic diseases companies have focused on to date. It’s called Kriya Therapeutics.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 83,000+ biopharma pros reading Endpoints daily — and it's free.